Why This FDA Clearance Is a Big Deal For Sorrento Therapeutics
Sorrento Therapeutics has announced that its treatment for COVID-19 had cleared its Phase 2 study in hospitalized patients with moderate to severe coronavirus infections.
Sorrento Therapeutics has announced that its treatment for COVID-19 had cleared its Phase 2 study in hospitalized patients with moderate to severe coronavirus infections.
GlaxoSmithKline has announced that it is acquiring a 10% stake in the German biopharma firm CureVac.
BioNTech and Pfizer are leading the pack of COVID-19 vaccine stocks as this collaboration came out with more positive news regarding their ongoing German Phase 1/2 study.
As the COVID-19 pandemic continues around the world, and the number of cases in the United States rises relentlessly, there are now three countries that have over a million confirmed cases.
These four sizzling biotech stocks trading under the $10 level have big upside to the analysts' price targets. All of them are rated Buy at Goldman Sachs.
PhaseBio Pharmaceuticals announced early on Friday that it has initiated its midstage study evaluating a treatment for the novel coronavirus.
The number of COVID-19 cases continues to rise, which will only create more demand for coronavirus stocks. 24/7 Wall Street has picked out a few of the best and brightest that could still see…
Almost as many people have died from COVID-19 in America this year as die from stroke, the fifth-largest killer in the country, in a full year.
Johnson & Johnson released better than expected quarterly results and guidance before the markets opened on Thursday.
Confirmed COVID-19 cases in New York State have topped 400,000, more than any other state. It also leads the country in fatal cases.
Immutepjoins the ever-growing list of coronavirus stocks by announcing that it was granted a patent related to COVID-19 antibodies.
Moderna made another big step forward in the fight against COVID-19 after the company reported incredibly positive data from the early-stage trial of its coronavirus vaccine.
UnitedHealth Group released mixed second-quarter financial results and maintained its guidance before the markets opened on Wednesday.
In a sign of how quickly COVID-19 has spread among America's largest states, confirmed cases in California number nearly half of the count in Russia.
IMV shares surged on Tuesday after the company provided an update on its vaccine candidate for COVID-19.